SCHEMBL30911486

SCHEMBL30911486

OC1CCN(c2cc(Cl)ncc2I)CC1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ IRAK4 Q9NWZ3 2/20 0.39
▸ SMO Q99835 2/20 0.38
▸ HSP90AA1 P07900 1/20 0.36
▸ HSP90AB1 P08238 1/20 0.36
▸ F10 P00742 1/20 0.36
▸ ATR Q13535 2/20 0.35
▸ ATRIP Q8WXE1 1/20 0.35
▸ SMARCA2 P51531 1/20 0.35
▸ SMARCA4 P51532 1/20 0.35
▸ PBRM1 Q86U86 1/20 0.35
▸ PTPN11 Q06124 1/20 0.34
▸ HTT P42858 2/20 0.33
▸ LMNA P02545 1/20 0.33
▸ CCNT1 O60563 1/20 0.33
▸ GPR6 P46095 1/20 0.33
▸ PIK3CA P42336 1/20 0.33
▸ STK4 Q13043 1/20 0.33
▸ STK3 Q13188 1/20 0.33
▸ LRRK2 Q5S007 1/20 0.33
▸ KCNH2 Q12809 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30911597 0.91 IRAK4 (0.41) IRAK4SMOATRCHEK1ABL1
SCHEMBL30911502 0.86 ALDH1A1 (0.33) IRAK4ATRHTTGPR6PIK3CA
SCHEMBL30911509 0.84 IRAK4 (0.41) IRAK4PIK3CA
SCHEMBL30911543 0.82 IRAK4 (0.42) IRAK4SMARCA2SMARCA4PBRM1LMNA
SCHEMBL31262524 0.82 IRAK4 (0.42) IRAK4SMARCA2SMARCA4PBRM1LMNA
SCHEMBL30911690 0.81 IRAK4 (0.43) IRAK4ATRHTTGPR6PIK3CA
SCHEMBL30911592 0.81 ATR (0.40) IRAK4ATRATRIPGPR6PIK3CA
SCHEMBL31262618 0.81 IRAK4 (0.34) IRAK4ATRATRIPGPR6KCNH2
SCHEMBL30911583 0.81 ATR (0.38) ATRATRIPHTTGPR6PIK3CA
SCHEMBL31262589 0.81 KDM4E (0.39) IRAK4HTTGPR6PIK3CAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117980297-A Substituted aminopyridine compounds as EGFR inhibitors 柳韩洋行 2024-05-03 — — CN disclosed
Send feedback